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Abstract
Background: Allergen-specific immunotherapy (AIT) still remains the only causal treatment for IgE mediated
respiratory diseases (rhinitis/asthma) In addition to the observed clinical decrease in symptoms, AIT can provide a
long-lasting and preventive effect. In particular it can modify the progression from rhinitis to asthma.
Methods: The study was observational, open, non randomized, controlled, prospective and performed in a real-life
setting. Patients with pure mite-induced allergic rhinitis were followed-up, receiving adjuvanted SLIT (aSLIT),
standard SLIT (sSLIT) or drug treatment alone, according to their preference starting between 2008 and 2009. The
possible onset of asthma, changes in pulmonary function and bronchial hyperreactivity (BHR) were assessed over a
5-year horizon. Also the onset of new sensitizations and symptoms-medication score (SMS) were evaluated.
Results: One hundred forty two patients fulfilling the inclusion criteria were assessed at baseline, and 124
had the 5-year evaluation (age range 8–57, 69 male). After 5 years of treatment, new sensitizations appeared differentially
among treatments with 58.1% of new sensitizations in the drug treatment group, 13.2% in the sSLIT patients, and 8.1% in
the aSLIT patients. At the end of 5 years, SMS significantly changed (P < 0.001) in all groups, with a negative trend for
controls, as compared to the SLIT treatments. The SMS decreased in both SLIT groups at 5 years, with no change in
patients on drug treatment alone. The use of salbutamol (absent at baseline), showed an overall increase only in the
group receiving drugs alone with a significant difference at 5 years (P < 0.001). Considering the MCh challenge, there was
a difference among treatments (P < 0.001) in PD20 after 5 years: the control group had a lower PD20 at 5 years. No
significant difference in PD20 was detected between sSLIT and aSLIT. The FEV1 significantly decreased in controls, with no
change in the sSLIT group and a significant increase in aSLIT as compared to sSLIT.
Discussion: Despite the limitations inherent to a real-life setting study (absence of randomization and control, small
sample size, lack of intermediate timepoint assessment) the results of this study evidenced that the investigated SLIT
product, either adjuvanted or not, had a positive effect on the evolution of respiratory allergy due to house dust mite.
Conclusion: In the real life setting, considering a 5-year period, aSLIT and sSLIT reduced the onset of new
sensistizations and maintained intact the pulmonary function, as compared to patients receiving drug treatment alone.
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Background
Allergen-specific immunotherapy (AIT) still remains the
only causal treatment for IgE mediated diseases, namely
respiratory (rhinitis/asthma) and hymenoptera venom
allergy [1–3]. The clinical effects of AIT relies on its
complex mechanisms of action, involving the cellular
and humoral response to the responsible antigens [4].
AIT reduces the severity of IgE mediated reactions and
the subsequent inflammation, by redirecting the T-cell
responses, increasing the secretion of regulatory cyto-
kines, and the synthesis of allergen specific IgG4 (that
blocks the IgE facilitated antigen presentation) [4, 5]. In
addition to the observed clinical decrease in symptoms,
AIT can provide a long-lasting and preventive effect
[6]. In particular it can modify the progression from
rhinitis to asthma. Currently, both the subcutaneous
(SCIT) and the sublingual (SLIT) routes are validated
and accepted for clinical use. In parallel, several im-
provements have been proposed, including new routes
of administration, recombinant molecules and adju-
vants [7]. Adjuvants, in particular, are expected to en-
hance the antigenic effect of the allergen, reinforcing
the skew towards the TH1 phenotype. Bacterial wall-
derived adjuvants, that engage the toll-like receptors 9
(TLR-9) [8], have displayed an additional clinical effect
in clinical trials, and in fact commercial products are
now available. This effect has been recently applied also
to SLIT, but the long-lasting and preventive effects have
never been studied in the real-life setting.
In this prospective, open, real-life setting observational
study we assessed the disease modifying effect (changes
in respiratory function, onset of bronchial hyperreactiv-
ity, onset of new sensitizations) in patients monosensi-
tized to dust mites and with pure allergic rhinitis over a
5-year period, receiving both natural or adjuvanted
SLIT.
Methods
The study was observational, open, prospective, per-
formed in a real-life setting and therefore not random-
ized. Three groups of patients with mite-induced
allergic rhinitis (AR) were followed-up, receiving adju-
vanted SLIT (aSLIT), standard SLIT (sSLIT) or drug
treatment alone, starting between 2008 and 2009. The
possible onset of asthma, changes in pulmonary func-
tion and bronchial hyperreactivity (BHR) were assessed
over a 5-year horizon. Also the onset of new sensitizations
was evaluated. The observational study was performed at
the Ospedale di Cuasso al Monte- Azienda Ospedaliera
Fondazione Macchi-Varese, Italy. Since the study used the
standard of care, no Ethical Committee evaluation was re-
quired. All patients signed an informed consent for the
treatment of personal data, as per usual procedure.
We evaluated consecutive patients monosensitized to
house dust mite (HDM), confirmed by positive skin
prick test and/or CAP-RAST assay, and suffering from
moderate/severe persistent allergic rhinitis. None had
asthma [9, 10], as documented by clinical history, pul-
monary function test (PFT) and methacholine (MCh)
challenge. Skin prick test were performed using a com-
mercial panel of extracts (Alk Abellò, Lainate, Milan,
Italy), including HDM, grass, birch, parietaria, cypress,
ragweed, alternaria, cat and dog dander. The results
were read as per recommendations. Patients had to have
a forced expiratory volume in 1 s (FEV1) > 80% of pre-
dicted, and a negative MCh challenge that is a provoca-
tive dose causing a 20% fall in FEV1 (PD20) >1290 mcg.
Patients with malignancies, autoimmune diseases or
immune-deficiencies nasal mechanical abnormalities
(septal deviation, polyps), cardiovascular or psychiatric
disorders, pregnancy, were considered not eligible for
AIT [1–3]. After the diagnosis of allergic rhinitis was
established (years 2008–2009), SLIT was proposed to pa-
tients as per guidelines. They could chose to start or not
the SLIT course, administered as drops. According to
their personal decision, patients received the aSLIT
(Anallergo, Florence, Italy) or the standard (not adju-
vanted) sSLIT (Anallergo, Florence, Italy) or drug
treatment alone. All patients received cetirizine 10 mg
(1 tablet/day) and budesonide nasal spray (100 mcg/
nostril twice daily). Also, inhaled salbutamol (100 mcg
2–4 actuations) was prescribed in the case of unex-
pected asthma episodes. The SLIT course lasted
5 years, and parameters (diary card, PFT, MCh, skin
test) were therefore assessed at baseline and after
5 years. The clinical diary was recorded from November
to February (expected maximal exposure to mites) at
baseline and after 5 years. Rhinorrhea, itching, sneezing,
obstruction, conjunctival itching, tearing, wheezing and
cough were graded from 0 (absent) to 3 (troublesome).
Each dose of the prescribed medications was scored 1.
The monthly mean of symptoms +medications score
(SMS) was used for statistics. PFT and MCh challenge
were carried out according to guidelines [11], by a com-
puterized spirometer and dosimeter (Masterlab Yaeger,
Wurtzburg, Germany).
Pearson Chi-square was used to compare gender dis-
tribution, drop-off and new sensitization frequencies
across groups, whereas ANOVA was used to initially test
differences of means among different treatments at base-
line. Normality was tested using Kolmogorov Smirnov
test, whereas the homoscedasticity was tested using the
Welch’ test. The effects of different treatments after
5 years were tested using a Generalized Linear Model
for repeated measures to compare within and between
factors effects. Post Hoc tests were conducted using a
Sidak correction for multiple comparisons [12]. When
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variability comparisons were needed, interquartile distances
were computed by using the Tukey’s Hinges. Probability
levels for Pearson Chi-square and Kolmogorov-Smirnov
tests were computed using a complete randomisation
method [13].
Results
One hundred and forty two patients fulfilling the inclu-
sion criteria were assessed at baseline, and 124 had the
5-year evaluation (mean age 27, age range 8–57, 69
male). No significant difference was detected in baseline
values for gender (X2 = 0.140, df = 2, PExact = 0.948) or
age (F = 0.400, P = 0.671) (Table 1). At the end of the ob-
servation period of 5 years (completed SLIT course),
there were 9 drop-out in the drug treatment group
(22.5%), 5 in the sSLIT (11.5%) and 4 (9.7%) in the
aSLIT group, with no statistical difference (X2 = 3.092,
df = 2, PExact = 0.219). No age effect was detected for any
of the examined parameters (GLM P > 0.05). After
5 years of treatment, new sensitizations appeared dif-
ferentially among treatments (X2 = 20.815, df = 2, PExact
< 0.001), with 58.1% (18/31) of new sensitizations in
the drug treatment group, in 13.2% (5/38) in the sSLIT
patients, and in 8.1% (3/37) in the aSLIT patients
(Table 2). The majority of new sensitizations were due
to grasses and birch, as expected in this geographic
area. At the end of 5 years, SMS significantly changed
(F = 17.922, P < 0.001) in all groups, but with a negative
trend for controls, as compared to the SLIT treatments
(F = 66.916, P < 0.001). The SMS decreased in both
SLIT groups at 5 years, with no change in patients on
drug treatment alone (Fig. 1). Across the groups, an
overall highly significant difference among treatments
was detectable (F = 61.600, P <0.001), mostly due to
the fact that the patients receiving drugs alone had
more symptoms than the two SLIT groups (Post Hoc
Sidak correction: drugs vs. sSLIT, mean difference
142.3, P < 0.001; drugs vs. aSLIT, mean difference
147.4, P < 0.001). There was no significant difference
between sSLIT and aSLIT. Of note, the use of
salbutamol (absent at baseline), showed an overall in-
creased consumption only in the group receiving drugs
alone (Table 3), with a significant difference in 2014
(F2,105 = 18.705, P < 0.001). Considering the MCh challenge,
there was a modest effect of time (F = 4.034, P = 0.047), but
a large difference among treatments (F = 21.676, P < 0.001)
in PD20 after 5 years (Fig. 2), again due mostly to the con-
trol group that had a lower MCH PD20 at 5 years (F =
18.821, P <0.001; post hoc tests with Sidak’s correction,
P < 0.001). No significant difference in PD20 was de-
tected between sSLIT and aSLIT (post hoc test with
Sidak’s correction, P > 0.050). The FEV1 was signifi-
cantly decreased in controls, with no change in the
sSLIT group and a significant increase in aSLIT as com-
pared to sSLIT (Fig. 3) (post hoc tests with Sidak’s cor-
rection, P < 0.001).
Discussion
Main results of this real-life observational study in pa-
tients with pure allergic rhinitis due to mite were: a) a
reduction of combined symptoms +medication scores of
rhinitis, recorded for 4 months at baseline and after
5 years with both the SLIT products was seen; b) the on-
set of new sensitizations at SPT was significantly lower
Table 1 Demographic and clinical characteristics of the 124 subjects having the complete data at baseline and at 5 years.
Significant P values for One way ANOVA are reported; ns: P > 0.05
Control sSLIT aSLIT P
Sex F 17 20 18 ns
M 23 23 23
Age Mean (SEM) 27.08 (1.74) 26.09 (1.83) 24.83 (1.71) ns
SMSa Mean (SEM) 291.03 (10.81) 283.58 (14.13) 305.78 (10.89) ns
MCH
PD20b
Mean (SEM) 1951.98 (35.07) 1958.33 (35.51) 1988.56 (34.75) ns
FEV1c Mean (SEM) 95 (0.97) 94.44 (1.06) 96.73 (0.81) ns
aSymptom +Medication Score
bMCh PD20: provocation dose causing a FEV1 20% decrease
cFEV1: Forced expiratory volume in 1 s (% predicted)
Table 2 New sensitizations occurred at 5 years subdivided per
allergen. The last row reports the number and percentage of
patients with at least one new sensitization
aSLIT n = 37 sSLIT n = 38 Control N = 31
Grass 1 3 8
Birch 2 3 6
Cat 1 3 3
Alternaria 1 1 4
Parietaria 1 - 2
Olive - - 1
Ragweed - 1 2
Dog 1 1 1
Total patients (%) 3 (8.1) 5 (13.2) 18 (58.1)
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in the SLIT groups than in the control group; c) there
was a significant decrease in MCh PD20 (that is an in-
crease in bronchial hyperreactivity) only in those pa-
tients not receiving SLIT; d) a small but significant
decrease in FEV1 was seen only in patients treated
with symptomatic drugs only; e) the intake of salbuta-
mol, although low, increased in the drug only group
after 5 years.
Pending the limitations due to the real-life experimen-
tal framework, the information is of clinical relevance,
since it confirms that AIT (SLIT in the present case)
may affect the onset of asthma and intervene on the
lung function. To our knowledge, this is the only study
evaluating unselected patients at 5 years after starting
AIT using also objective parameters. Considering the
real-life setting, that requires the use of standard of care
procedures only, no randomization or blinding was
made. Also, there were no selection criteria, but the eli-
gibility to receive AIT according to guidelines. This
observational study has, therefore, the unavoidable limi-
tations of all studies that are conducted in a real life
setting, with standard procedures and standard of care.
In such studies, blinding and placebo control are not
feasible, and interim parameters are lacking, since they
cannot be obtained for all patients. On the other hand,
the small number of patients lost to follow-up after
5 years, indirectly testifies for the persistence of subjects
with the prescribed care. Also, there was no
randomization procedure, and the type of treatment was
agreed with patients by physicians in all cases. The
strengths reside in the long period of observation, in the
fact that objective measures were performed, and that
the observations were performed in unselected patients,
seen at a territorial Unit.
AIT (either SLIT and SCIT) has been robustly demon-
strated clinically effective in reducing symptoms and
medication consumption in respiratory allergy [1–3],
and the magnitude of this effect has been largely
Table 3 Evaluated parameters at 5 years in the 3 groups (mean, standard errors of means, 95% confidence intervals of the mean,
and minimum and maximum values)
Mean Std.
Error
95% Confidence Interval for Mean Minimum Maximum
Lower Bound Upper Bound
SMS Drugs 345.16 19.526 305.28 385.04 121 470
sSLIT 86.47 14.579 56.93 116.01 13 299
aSLIT 41.08 13.976 12.74 69.43 7 370
Total 146.28 15.532 115.49 177.08 7 470
MCh PD20 Drugs 925.48 152.588 613.86 1237.11 68 2380
sSLIT 1769.84 101.384 1564.42 1975.27 186 2443
aSLIT 1936.65 75.278 1783.98 2089.32 192 2394
Total 1581.13 75.241 1431.94 1730.32 68 2443
FEV1 Drugs 87.45 1.585 84.22 90.69 76 106
sSLIT 95.05 1.172 92.68 97.43 81 113
aSLIT 104.11 1.268 101.54 106.68 87 117
Total 95.99 1.000 94.01 97.97 76 117
BETA2 Drugs 5.13 1.226 2.63 7.63 0 19
sSLIT .32 .156 .00 .63 0 4
aSLIT .16 .099 −.04 .36 0 3
Total 1.67 .421 .84 2.50 0 19
Fig. 1 Changes in mean monthly symptoms scores (SMS) in the 3
groups of patients at baseline and after treatment. Boxes represent
the interquartile range, thick line represents the 2nd quartile (median);
whiskers represent extreme values; outliers are represented as empty
dots (more than 1.5 times the interquartile distance) or as asterisks
(above 3 times the interquartile range). P values indicated above boxes
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confirmed in the so-called “big trials” conducted with
grass, ragweed and mite [6, 14]. According to this, sev-
eral extracts have been approved as pharmacological
products by the European Medicine Agency and the
Food and Drug Administration [15]. The majority of tri-
als were conducted in rhinitis and with pollen extracts,
and fewer in asthma and with mites [16, 17]. The reason
of this, stands in the fact that with mites there are more
methodological problems, including the variable expos-
ure and the need for long periods of observation [18]. In
addition, asthma is more difficult to assess, since object-
ive measures (PFT) are needed [19]. Nonetheless,
consistent data supported the effect of AIT in this dis-
ease [16, 17]. Another aspect, linking rhinitis, asthma
and AIT is that rhinitis is a strong and independent risk
factor for developing asthma [20] and AIT can intervene
on this progression [6]. The use of adjuvants in AIT was
repeatedly proposed (for review see [21, 22]), and some
products containing bacterial adjuvants are already com-
mercialized and used [23]. In general, the addition of an
adjuvant allows to reduce the total dose of allergen to be
administered, by enhancing the TH1 response via toll
like receptors stimulation [24].
In the present observational trial, conducted in real life
and using standard of care procedures, we evaluated the
effects of SLIT (using two marketed products, one with
bacterial adjuvants) on respiratory function in patients
with pure allergic rhinitis due to mites at baseline, and
we observed a preventative effect on the development of
new sensitizations, asthma symptoms and changes in
pulmonary function.
Conclusion
In conclusion, when assessed in a real life setting, both
sSLIT and aSLIT showed a preventative effect on pul-
monary function changes over a 5-year period, in pa-
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Fig. 2 Changes in MCh PD20. in the 3 groups of patients at baseline
and after treatment. Boxes represent the interquartile range, thick line
represents the 2nd quartile (median); whiskers represent extreme
values; outliers are represented as empty dots (more than 1.5 times
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Fig. 3 Changes in FEV1. in the 3 groups of patients at baseline and
after treatment. Boxes represent the interquartile range, thick line
represents the 2nd quartile (median); whiskers represent extreme
values; outliers are represented as empty dots (more than 1.5
times the interquartile distance) or as asterisks (above 3 times the
interquartile range). P values indicated above boxes
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